$0.18
4.49% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US62818Q1040
Symbol
MBIO
Sector
Industry

Mustang Bio, Inc. Stock price

$0.18
-0.01 3.21% 1M
-0.28 60.50% 6M
-1.17 86.38% YTD
-1.15 86.17% 1Y
-26.22 99.30% 3Y
-57.12 99.68% 5Y
-146.82 99.87% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.01 4.49%
ISIN
US62818Q1040
Symbol
MBIO
Sector
Industry

Key metrics

Market capitalization $9.12m
Enterprise Value $6.57m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-21.44m
Free Cash Flow (TTM) Free Cash Flow $-16.70m
Cash position $3.53m
EPS (TTM) EPS $-1.79
Short interest 0.54%
Show more

Is Mustang Bio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Mustang Bio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Mustang Bio, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Mustang Bio, Inc.:

Buy
100%

Financial data from Mustang Bio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 1.46 1.46
47% 47%
-
-1.46 -1.46
47% 47%
-
- Selling and Administrative Expenses 4.54 4.54
33% 33%
-
- Research and Development Expense 14 14
71% 71%
-
-20 -20
66% 66%
-
- Depreciation and Amortization 1.46 1.46
47% 47%
-
EBIT (Operating Income) EBIT -21 -21
65% 65%
-
Net Profit -23 -23
63% 63%
-

In millions USD.

Don't miss a Thing! We will send you all news about Mustang Bio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mustang Bio, Inc. Stock News

Neutral
GlobeNewsWire
about 2 months ago
WORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced that by decision dated November 8, 2024, the Nasdaq Hearings Panel granted the Company's request fo...
Neutral
GlobeNewsWire
about 2 months ago
MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial
Neutral
GlobeNewsWire
2 months ago
WORCESTER, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to pu...
More Mustang Bio, Inc. News

Company Profile

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in Worcester, MA.

Head office United States
CEO Manuel Litchman
Employees 80
Founded 2015
Website www.mustangbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today